My Compassion, a nonprofit organization, prepares for the Chicago Cannabis Conference on Navy Pier this weekend. The first conference of its kind, speakers include: state representatives, doctors, lawyers, and industry professionals advocating the forward movement of responsibility and professionalism in a previously forbidden realm.

(http://www.chicagotribune.com/news/local/breaking/chi-cannabis-conference-at-navy-pier-this-weekend-20140606,0,981239.story)

The UK-based GW pharmaceuticals has announced plans to implement their product Epidiolex in US markets. Epidiolex is a cannabidiol (CBD) extract used to treat childhood epilepsy resulting from Dravet syndrome. Currently, Epidiolex is in use by only seven patients in the US under unique legal circumstances. As of today, the United States’ FDA has approved Epidiolex for “fast track designation”, which expedites the availability of breakthrough treatments.

(http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/10880133/GW-Pharmaceuticals-cannabis-based-drug-Epidiolex-to-be-fast-tracked-in-US.html)